Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

March 31, 2013

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

CJC-1134-PC Injection

CJC-1134-PC administered weekly by subcutaneous injection

DRUG

Weekly placebo for CJC-1134-PC Injection

Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection

Trial Locations (22)

16602

Research Site, Altoona

23233

Research Site, Henrico

27405

Research Site, Greensboro

29407

Research Site, Charleston

29687

Research Site, Taylors

33414

Research Site, Wellington

40504

Research Site, Lexington

75231

Research Site, Dallas

78249

Research Site, San Antonio

78758

Research Site, Austin

83404

Research Site, Idaho Falls

84107

Research Site, Salt Lake City

85018

Research Site, Phoenix

90301

Research Site, Inglewood

91356

Research Site, Tarzana

93003

Research Site, Ventura

97401

Research Site, Eugene

02135

Research Site, Brighton

02915

Research Site, East Providence

Unknown

Research Site, Vancouver

Research Site, Smiths Falls

Research Site, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ConjuChem

INDUSTRY